Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce ... reduce the risk of complications in patients with chronic kidney disease, an indication for which it has been filed ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as ... has approvals in cardiovascular disease and chronic kidney disease and is looking at various other indications ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Reports Q4 revenue $13.53B, consensus $13.43B. “2024 was a highly successful year for Lilly,” said David Ricks, Lilly’s chair and CEO. “We had ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Eli Lilly, after tirzepatide's late-stage cardio win ... blood clotting, liver cancer, kidney disease, bacterial infections, pneumonia and Parkinson’s disease, according to the researchers.